Response to: ' HLA-A 31:01* is not associated with the development of methotrexate pneumonitis in the UK population: results from a genome wide association study' by Bluett et al

Ann Rheum Dis. 2017 Dec;76(12):e52. doi: 10.1136/annrheumdis-2017-211518. Epub 2017 May 12.

Authors

Hiroshi Furukawa^{1

2}, Shomi Oka^{1

2}, Kota Shimada^{3

4}, Naoyuki Tsuchiya¹, Shigeto Tohma²; Rheumatoid Arthritis associated Interstitial Lung Disease (RA-ILD) Study Consortium

Affiliations

¹ Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
² Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Sagamihara, Japan.
³ Department of Rheumatology, Sagamihara National Hospital, National Hospital Organization, Sagamihara, Japan.
⁴ Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Fuchu, Japan.

PMID: 28500058
DOI: 10.1136/annrheumdis-2017-211518

No abstract available

Keywords: Disease Activity; Methotrexate; Treatment.

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Arthritis, Rheumatoid*
Genome-Wide Association Study
HLA-A Antigens
Humans
Lung Diseases, Interstitial*
Methotrexate
Pneumonia*
United Kingdom

Substances

HLA-A Antigens
Methotrexate